Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.19

-1.4%

Dec 30 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (10735)	3/1/2004 1:26:19 PM
From: Biomaven	Read Replies (1) of 52153

I see no reason to have confidence in sepr nce chemistry capabilities. Well given that this isn't a real big emphasis of theirs, it does seem to me that they've had a decent number of compounds at least nearing the clinic. Of course it's hard to keep track of what's an NCE and what's some metabolite of an existing drug. The POZN drugs are all for treatment of acute migraine. The SEPR candidate is for prophylaxis. On that side there hasn't been a new drug in decades, except for some moderate success using some of the new anti-epileptics like Topamax. It's a tough area to do trials in - big placebo response if the patients are newbies, or refractory-to-everything-else if they are not. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next